Yazar "Gucenmez S." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Imaging findings of pulmonary granulomatosis with polyangiitis (Wegener’s granulomatosis): lesions invading the pulmonary fissure, pleura or diaphragm mimicking malignancy
    (Springer-Verlag Wien, 2016) Guneyli S.; Ceylan N.; Bayraktaroglu S.; Gucenmez S.; Aksu K.; Kocacelebi K.; Acar T.; Savas R.; Alper H.
    Background: Granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis), in which pulmonary involvement often predominates, is a multisystem granulomatous, necrotizing vasculitis that affects small and medium-sized vessels. In this study we evaluated various radiological findings of pulmonary GPA and focused on spiculated pulmonary lesions invading the pulmonary fissure, pleura or diaphragm mimicking malignancy. Methods: This retrospective study included 48 patients, aged 28–73 (mean, 47.3) years, who showed either histopathological diagnosis of GPA (n = 39) or elevated levels of the cytoplasmic anti-neutrophilic cytoplasmic antibody serum marker (n = 9) between January 2003 and December 2013. All patients received a chest computed tomography (CT), and the types of pulmonary lesions were defined and evaluated. Results: Among the 48 patients, 33 had abnormal pulmonary findings on CT. The most commonly detected pulmonary lesion types were nodules and masses (n = 126) observed in 24 patients. Cavitation, necrosis, spiculation and invasion of the fissure, pleura or diaphragm were observed in 14, 9, 10 and 6 patients, respectively. Consolidation was found in 14 patients and thickening of bronchial wall in 8 patients. Conclusions: Pulmonary lesion types of GPA have a wide spectrum, potentially mimicking a high number of diseases including malignancy, infection and noninfectious inflammatory diseases. A spiculated lung lesion invading the fissure, pleura or diaphragm is mostly present in malignancy, but it can be also seen in GPA. © 2015, Springer-Verlag Wien.
  • Küçük Resim Yok
    Öğe
    Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases
    (Journal of Rheumatology, 2015) Yilmaz N.; Emmungil H.; Gucenmez S.; Ozen G.; Yildiz F.; Balkarli A.; Kimyon G.; Coskun B.N.; Dogan I.; Pamuk O.N.; Yasar S.; Cetin G.Y.; Yazici A.; Esmen S.E.; Cagatay Y.; Yilmaz S.; Cefle A.; Sayarlioglu M.; Kasifoglu T.; Karadag O.; Pehlivan Y.; Dalkilic E.; Kisacik B.; Cobankara V.; Erken E.; Direskeneli H.; Aksu K.; Yavuz S.
    Objective. To assess bladder toxicity of cyclophosphamide (CYC) and uroprotective effect of mesna in rheumatic diseases. Methods. Data of 1018 patients (725 women/293 men) treated with CYC were evaluated in this retrospective study. All of the following information was obtained: the cumulative CYC dose, route of CYC administration, duration of therapy, concomitant mesna usage, and hemorrhagic cystitis. Cox proportional hazard model was used for statistics. Results. We identified 17 patients (1.67%) with hemorrhagic cystitis and 2 patients (0.19%) with bladder cancer in 4224 patient-years. The median time for diagnosis to hemorrhagic cystitis was 10 months (4-48) and bladder cancer was 8 years (6-10.9). There were 583 patients (57.2%) who received mesna with intravenous CYC therapy. We observed similar incidence rate for hemorrhagic cystitis in both patient groups concomitantly treated with or without mesna [9/583 (1.5%) vs 8/425 (1.8%) respectively, p = 0.08]. Cumulative CYC dose (HR for 10-g increments 1.24, p < 0.001) was associated with hemorrhagic cystitis. Conclusion. Cumulative dose was the only risk factor for hemorrhagic cystitis in patients treated with CYC. No proof was obtained for the uroprotective effect of mesna in our cohort. © 2015 All rights reserved.